Yinli Yang

748 total citations
17 papers, 584 citations indexed

About

Yinli Yang is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Yinli Yang has authored 17 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Yinli Yang's work include Hepatitis B Virus Studies (4 papers), Immune Cell Function and Interaction (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Yinli Yang is often cited by papers focused on Hepatitis B Virus Studies (4 papers), Immune Cell Function and Interaction (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Yinli Yang collaborates with scholars based in China. Yinli Yang's co-authors include Qiuju Han, Cai Zhang, Zhansheng Jiang, Zhigang Tian, Jian Zhang, Zhaohua Hou, Ling Li, Xiubao Ren, Bin Wang and Yu Zhang and has published in prestigious journals such as European Journal of Cancer, Journal of Leukocyte Biology and Biomedicine & Pharmacotherapy.

In The Last Decade

Yinli Yang

17 papers receiving 575 citations

Peers

Yinli Yang
Lubiao Chen China
Kazuma Sekiba Japan
Ben Zhao China
Jesús Ontañón Spain
Shengzheng Luo China
Te‐Sheng Chang Taiwan
Xiaoxin Mu China
Yun Liao China
Jianling Yang China
Shuangyi Ren China
Lubiao Chen China
Yinli Yang
Citations per year, relative to Yinli Yang Yinli Yang (= 1×) peers Lubiao Chen

Countries citing papers authored by Yinli Yang

Since Specialization
Citations

This map shows the geographic impact of Yinli Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinli Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinli Yang more than expected).

Fields of papers citing papers by Yinli Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinli Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinli Yang. The network helps show where Yinli Yang may publish in the future.

Co-authorship network of co-authors of Yinli Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Yinli Yang. A scholar is included among the top collaborators of Yinli Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinli Yang. Yinli Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Jiang, Zhansheng, et al.. (2025). Anlotinib induced ferroptosis through the p53/xCT/GPX4 pathway in non-small cell lung cancer. Translational Oncology. 53. 102289–102289. 3 indexed citations
2.
Wang, Bin, Yue Pan, Yongjie Xie, et al.. (2024). Metabolic and Immunological Implications of MME+CAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportunities. Biological Procedures Online. 26(1). 29–29. 6 indexed citations
3.
Jiang, Zhansheng, Jiahe Wang, Mingyu Zhu, et al.. (2024). Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma. APOPTOSIS. 29(5-6). 681–692. 14 indexed citations
4.
Sun, Haiyan, Peng Ren, Yongzi Chen, et al.. (2023). Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer. 23(1). 198–198. 13 indexed citations
5.
Huang, Jin, Shanshan Li, Yongming Guo, et al.. (2020). The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice. Evidence-based Complementary and Alternative Medicine. 2020(1). 3170803–3170803. 12 indexed citations
6.
Yang, Yinli, et al.. (2020). Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunology Immunotherapy. 69(12). 2523–2532. 83 indexed citations
7.
Wang, Cong, Yinli Yang, Lining Sun, et al.. (2020). Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy. Cancer Cell International. 20(1). 35–35. 14 indexed citations
8.
Yang, Yinli, et al.. (2020). Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Gene Therapy. 28(1-2). 89–97. 19 indexed citations
9.
Wang, Kaiyuan, Yinli Yang, Jian Wang, et al.. (2019). Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis. Frontiers in Oncology. 9. 235–235. 8 indexed citations
10.
Zheng, Bingqing, et al.. (2019). STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients. Journal of Leukocyte Biology. 106(4). 987–996. 25 indexed citations
11.
12.
Jiang, Zhansheng, et al.. (2017). Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomedicine & Pharmacotherapy. 96. 378–383. 119 indexed citations
13.
Yang, Yinli, Bingqing Zheng, Qiuju Han, et al.. (2016). Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biology & Therapy. 17(4). 449–456. 28 indexed citations
14.
Yang, Yinli, Qiuju Han, Zhaohua Hou, et al.. (2016). Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cellular and Molecular Immunology. 14(5). 465–475. 181 indexed citations
15.
Yang, Yinli, Qiuju Han, Cai Zhang, Min Xiao, & Jian Zhang. (2016). Hepatitis B virus antigens impair NK cell function. International Immunopharmacology. 38. 291–297. 38 indexed citations
16.
17.
Qi, Da, Chun Huang, Yinli Yang, et al.. (2011). Removal notice to “Nimotuzumab in combination with docetaxel and carboplatin as treatment for advanced non-small-cell-lung-cancer” EJC Supp 9 (2011) 23. European Journal of Cancer. 47(16). 2491–2491. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lubiao Chen Breakdown of academic impact, for papers by Kazuma Sekiba Breakdown of academic impact, for papers by Ben Zhao Breakdown of academic impact, for papers by Jesús Ontañón Breakdown of academic impact, for papers by Shengzheng Luo Breakdown of academic impact, for papers by Te‐Sheng Chang Breakdown of academic impact, for papers by Xiaoxin Mu Breakdown of academic impact, for papers by Yun Liao Breakdown of academic impact, for papers by Jianling Yang Breakdown of academic impact, for papers by Shuangyi Ren
Rankless by CCL
2026